FDA proposes 50% fee cut for US early-stage trials, but industry says speed matters more

The FDA announced a proposal to cut the application fee by half for drugs that run their early-stage trials in the United States. The reduction, about $2.3 million at current rates, is intended to encourage companies to conduct Phase 1 development domestically, and a public meeting on the plan is scheduled for Sept. 16.

The author supports the goal of more U.S. early trials but questions the timing of the incentive. Offering the fee discount at the approval filing stage comes after the decision about where to locate Phase 1 studies has already been made, limiting its influence.

For small biotech firms, the more valuable incentive is speed. Faster results help identify ineffective biology early, reducing wasted investment, limiting patient exposure, and allowing resources to be redirected to more promising projects.

The commentary suggests that future PDUFA revisions should focus on mechanisms that accelerate the start and conduct of Phase 1 trials, aligning with the 2022 reauthorization language that calls for expediting the entire drug development process, not just the application phase.